IGRFX
Price
$32.39
Change
-$0.31 (-0.95%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

IGRFX vs RPTIX

Header iconIGRFX vs RPTIX Comparison
Open Charts IGRFX vs RPTIXBanner chart's image
Delaware Ivy Mid Cap Growth R6
Price$32.39
Change-$0.31 (-0.95%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
IGRFX vs RPTIX Comparison Chart
Loading...
VS
IGRFX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IGRFX is a StrongBuy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. IGRFX (6.7B). RPTIX pays higher dividends than IGRFX: RPTIX (0.18) vs IGRFX (0.00). IGRFX was incepted earlier than RPTIX: IGRFX (10 years) vs RPTIX (9 years). IGRFX is a more actively managed with annual turnover of: 23.00 vs. RPTIX (21.70). IGRFX has a lower initial minimum investment than RPTIX: IGRFX (0) vs RPTIX (500000). RPTIX annual gain was more profitable for investors over the last year : 14.81 vs. IGRFX (14.05). RPTIX return over 5 years is better than : 15.09 vs. IGRFX (10.17).
IGRFXRPTIXIGRFX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence10 years9 years-
Gain YTD5.2319.12757%
Front LoadN/AN/A-
Min. Initial Investment0500000-
Min. Initial Investment IRAN/AN/A-
Net Assets6.7B31.4B21%
Annual Yield % from dividends0.000.18-
Returns for 1 year14.0514.8195%
Returns for 3 years-30.52-13.57225%
Returns for 5 years10.1715.0967%
Returns for 10 years30.08N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp